RxDoctor Payments Data

Efrain Arroyo Pena, MD

General Practice · Mayaguez, PRNPI 1982745063

Payments from drug & device makers

$4,497in general payments, 2019–2025

Across 39 payments — averaging $115.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$4K
  • Viiv Healthcare Company$247
  • AbbVie$220
  • Johnson & Johnson$164
  • AstraZeneca$125
  • GSK$57
  • plus $140 from 7 others

What the payments were for

  • Consulting fees$3,36075%
  • Food & beverage$1,13725%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,497 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$2,134
Medicare patients
11
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala30$119,287
TivicayDolutegravir Sodium26$59,534
DescovyEmtricitabine/Tenofov Alafenam16$35,672
JardianceEmpagliflozin36$31,876
TradjentaLinagliptin23$21,486
XareltoRivaroxaban16$19,097
FarxigaDapagliflozin Propanediol20$17,470
SynthroidLevothyroxine Sodium117$10,170
LantusInsulin Glargine,hum.Rec.Anlog59$5,791
Albuterol Sulfate HfaAlbuterol Sulfate69$2,613
Glimepiride123$2,110
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,924
Atorvastatin Calcium189$1,804
Losartan Potassium185$1,653
Gabapentin237$1,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$3,544$154,95946 claims
Viiv Healthcare CompanyTivicay$247$59,53426 claims
Boehringer IngelheimJardiance, Tradjenta$16$53,36259 claims
Johnson & JohnsonXarelto$164$19,09716 claims
AstraZenecaFarxiga$125$17,47020 claims
AbbVieSynthroid$220$10,170117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →